Skip to content

US · LAB · MEDICAL - EQUIPMENT & SERVICES

Standard BioTools Inc. (LAB) intrinsic value and stock valuation

$0.63as of 2026-11-21 · Mkt cap 313.17M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Standard BioTools Inc. DCF and intrinsic value

InvestorsCraft values LAB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from LAB’s statements →

Standard BioTools Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Equipment & Services Boston, MA 02109 standardbio.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$85.3M-9.2% 5y CAGRd
20112025
Net income
-$-74.9M
20112025
Free cash flow
-$-82.65M
20112025
Total equity
$424.3M+25% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$85.3M$174.4M$106.3M$98M$130.6M
Operating income-$-93.31M-$-175.24M-$-76.6M-$-116.2M-$-67.46M
Net income-$-74.9M-$-138.88M-$-74.66M-$-190.1M-$-59.24M
EPSd-$-196.27K-$-393.8K-$-943.15K-$-2.43M-$-781.63K
Operating cash flow-$-74.35M-$-143.45M-$-43.29M-$-89.37M-$-44.06M
Capital expenditure-$-8.3M-$-8.36M-$-2.83M-$-3.83M-$-13.26M
Free cash flow-$-82.65M-$-151.81M-$-46.12M-$-93.19M-$-57.33M
Total assets$567.8M$612.3M$323.1M$390.3M$275.2M
Total debt$30.8M$33M$98.2M$102.7M$111.7M
Net debt-$-87.39M-$-133.73M$46.5M$21.4M$83.2M
Total equity$424.3M$471.7M-$-148.05M-$-81.47M$94.6M
Cash and short-term investments$187.6M$292.9M$114.9M$165.8M$28.5M
Income statement
20252024202320222021
Revenue$85.3M$174.4M$106.3M$98M$130.6M
Cost of revenue$42.8M$90.2M$55.9M$60.9M$61.2M
Gross profit$42.5M$84.3M$50.5M$37.1M$69.4M
Research and development expenses$26M$62.4M$26M$37.4M$37.9M
Selling, general and administrative expenses$109.9M$156.6M$87.5M$102.3M$98.9M
Other expenses$0.00$40.5M$13.6M$13.6M$0.00
Operating expenses$135.9M$259.5M$127.1M$153.3M$136.8M
Cost and expenses$178.6M$349.7M$182.9M$214.2M$198M
Interest income$9.18M$20.2M$5.57M$2.23M$0.00
Interest expense$30K$3.32M$4.57M$4.33M$3.82M
Depreciation and amortization$6.98M$16.9M$15.2M$15M$15.6M
Ebitda-$-89.69M-$-118.14M-$-54.46M-$-173.57M-$-44.27M
Operating income-$-93.31M-$-175.24M-$-76.6M-$-116.2M-$-67.46M
Total other income/expenses, net-$-3.4M$36.9M$2.4M-$-76.72M$3.8M
Income before tax-$-96.7M-$-138.31M-$-74.2M-$-192.93M-$-63.66M
Income tax expense-$-37.88M$570K$450K-$-2.83M-$-4.42M
Net income-$-74.9M-$-138.88M-$-74.66M-$-190.1M-$-59.24M
Weighted average shares outstanding$381.6M$352.7M$79.2M$78.3M$75.8M
Weighted average diluted shares outstanding$381.6M$352.7M$79.2M$78.3M$75.8M
Balance sheet
20252024202320222021
Cash and short-term investments$187.6M$292.9M$114.9M$165.8M$28.5M
Net receivables$13.4M$33.6M$19.7M$17.3M$18.3M
Inventory$20M$40.7M$20.5M$21.5M$20.8M
Total current assets$454.3M$375.9M$158.2M$208.8M$72.1M
Property, plant and equipment, net$46M$71.4M$54.9M$59.5M$65.2M
Goodwill and intangible assets$0.00$140.3M$107.7M$118.9M$134.3M
Long-term investments$25.7M$0.00$0.00$0.00$1M
Total non-current assets$113.5M$236.5M$164.9M$181.5M$203.2M
Total assets$567.8M$612.3M$323.1M$390.3M$275.2M
Accounts payable$5.41M$12.3M$9.24M$7.91M$10.6M
Short-term debt$5.49M$6.23M$63.9M$5.76M$9.89M
Deferred revenue$39M$18.6M$16.7M$14.4M$15.5M
Total current liabilities$108.3M$65.9M$109.3M$43.4M$49.6M
Long-term debt$25.3M$26.8M$34.4M$96.9M$101.8M
Deferred revenue, non-current$7.79M$39.9M$14.3M$18.2M$24.1M
Total non-current liabilities$35.2M$74.7M$361.8M$428.3M$131.1M
Capital lease obligations$25M$32.7M$34.7M$37.8M$40.6M
Total liabilities$143.5M$140.6M$471.1M$471.8M$180.6M
Common stock$400K$400K$80K$80K$80K
Retained earnings-$-1.26B-$-1.19B-$-1B-$-926.1M-$-736M
Accumulated other comprehensive income (loss)-$-1.49M$1.23M-$-2.22M-$-1.9M-$-910K
Total equity$424.3M$471.7M-$-148.05M-$-81.47M$94.6M
Total investments$95.1M$126.2M$63.2M$84.5M$1M
Total debt$30.8M$33M$98.2M$102.7M$111.7M
Net debt-$-87.39M-$-133.73M$46.5M$21.4M$83.2M
Cash flow statement
20252024202320222021
Net income-$-74.9M-$-138.88M-$-74.66M-$-190.1M-$-59.24M
Depreciation and amortization$1.72M$16.9M$15.2M$15M$16.2M
Stock-based compensation$29.6M$31.7M$13.1M$14.9M$16.1M
Change in working capital-$-44.98M-$-12.08M$1.79M-$-12.35M-$-18.01M
Accounts receivable-$-1.36M$8.97M-$-2.99M$1.06M$6.73M
Inventory-$-11.52M-$-9.88M-$-4.91M-$-8.47M-$-4.78M
Accounts payable$2.44M$0.00$1.62M$0.00$0.00
Net cash provided by operating activities-$-74.35M-$-143.45M-$-43.29M-$-89.37M-$-44.06M
Investments in property, plant and equipment-$-8.3M-$-8.36M-$-2.83M-$-3.83M-$-13.26M
Acquisitions, net$0.00$278.7M$0.00$0.00$0.00
Net cash used for investing activities$24.8M$363.2M$20.2M-$-88.13M-$-11.95M
Common stock issued$1.05M$0.00$0.00$0.00$0.00
Common stock repurchased$0.00-$-40.95M-$-5.41M-$-770K-$-1.79M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$570K-$-102.62M-$-6.81M$230.8M$16M
Net change in cash-$-48.17M$116.3M-$-29.82M$52.9M-$-40.07M
Cash at end of period$120.7M$168.8M$52.5M$82.3M$29.5M
Operating cash flow-$-74.35M-$-143.45M-$-43.29M-$-89.37M-$-44.06M
Capital expenditure-$-8.3M-$-8.36M-$-2.83M-$-3.83M-$-13.26M
Free cash flow-$-82.65M-$-151.81M-$-46.12M-$-93.19M-$-57.33M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Standard BioTools Inc.

        Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.

        CEO
        Michael Egholm
        Employees
        389
        Beta
        1.42

        Explore

        Frequently asked questions

        What is the intrinsic value of Standard BioTools Inc. (LAB)?

        InvestorsCraft does not currently publish an intrinsic value for LAB. How the IC value is calculated.

        Is LAB undervalued?

        InvestorsCraft does not publish an undervaluation signal for LAB at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.